Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 |
| recruiting |
| Phase 1 |
| 42 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Dec 11, 2025 |
| clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR T for mYeloma(MCARTY) | recruiting | Phase 1 | 27 | University College, LondonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06916767 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | recruiting | Phase 1 | 18 | Paolo Caimi, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05943496 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | recruiting | Phase 1 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma(CaMMouflage) | recruiting | Phase 1 | 50 | Caribou Biosciences, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06037018 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | recruiting | Phase 1 | 44 | CytoCares IncINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | recruiting | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT06616389 | Study of ODX (OsteoDex) in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 12 | DexTech Medical ABINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05565807 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05913804 | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | recruiting | Phase 1 | 36 | University Hospital TuebingenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07109323 | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05841550 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 84 | Cancer Research UKOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05759793 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2025source: clinicaltrials